Willis Johnson & Associates, Inc. Verona Pharma PLC Transaction History
Willis Johnson & Associates, Inc.
- $1.61 Billion
- Q3 2025
A detailed history of Willis Johnson & Associates, Inc. transactions in Verona Pharma PLC stock. As of the latest transaction made, Willis Johnson & Associates, Inc. holds 2,285 shares of VRNA stock, worth $244,289. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,285
Previous 2,285
-0.0%
Holding current value
$244,289
Previous $216,000
12.5%
% of portfolio
0.02%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
277Shares Held
77.3MCall Options Held
714KPut Options Held
449K-
Pentwater Capital Management LP Naples, FL5.3MShares$567 Million3.55% of portfolio
-
Hbk Investments L P Dallas, TX4.26MShares$456 Million6.29% of portfolio
-
Fil LTD Hamilton, D03.49MShares$373 Million0.32% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$362 Million15.27% of portfolio
-
Davidson Kempner Capital Management LP New York, NY3.27MShares$350 Million10.89% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.52B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...